OTCMKTS:NWPHF Newron Pharmaceuticals (NWPHF) Stock Price, News & Analysis → The Hidden Tax Advantages of America’s #1 Inheritance Stock (From Stansberry Research) (Ad) Free NWPHF Stock Alerts $9.55 0.00 (0.00%) (As of 06/11/2024 ET) Add Compare Share Share Today's Range$9.55▼$9.5550-Day Range$8.52▼$12.0052-Week Range$9.55▼$12.00VolumeN/AAverage Volume502 shsMarket Capitalization$170.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get Newron Pharmaceuticals alerts: Email Address Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About Newron Pharmaceuticals Stock (OTCMKTS:NWPHF)Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.Read More NWPHF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NWPHF Stock News HeadlinesMay 13, 2024 | finance.yahoo.comNewron Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia PatientsApril 8, 2024 | finance.yahoo.comData from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)March 19, 2024 | finance.yahoo.comNewron Presents 2023 Financial Results and Provides 2024 OutlookMarch 15, 2024 | finance.yahoo.comNewron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreementMarch 13, 2024 | finance.yahoo.comBreakeven Is Near for Newron Pharmaceuticals S.p.A. (VTX:NWRN)January 4, 2024 | finance.yahoo.comNewron Reports Exceptional One-year Results of Study 014/15 With Evenamide in Treatment-resistant Schizophrenia (TRS)January 2, 2024 | msn.comNewron enrols all subjects in schizophrenia treatment trialDecember 29, 2023 | markets.businessinsider.comEQS-News: Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with EvenamideDecember 13, 2023 | morningstar.comNewron Pharmaceuticals SpA NWRNOctober 9, 2023 | finance.yahoo.comNewron TRS Study 6 Months’ Results: Evenamide Substantially Improves Patients to an Extent That They No Longer Meet Protocol Entry CriteriaOctober 4, 2023 | businesswire.comNewron to Present Three Posters on Its Clinical Program Evaluating Evenamide in the Treatment of Schizophrenia at the 36 th European College of Neuropsychopharmacology CongressOctober 4, 2023 | finance.yahoo.comNewron to Present Three Posters on Its Clinical Program Evaluating Evenamide in the Treatment of Schizophrenia at the 36th European College of Neuropsychopharmacology CongressOctober 2, 2023 | markets.businessinsider.comEQS-News: Newron appoints Margarita Chavez as board advisorOctober 2, 2023 | finance.yahoo.comNewron Appoints Margarita Chavez as Board AdvisorAugust 4, 2023 | finance.yahoo.comNewron Announces H1 2023 Results and Provides R&D UpdateAugust 4, 2023 | markets.businessinsider.comEQS-News: Newron announces H1 2023 results and provides R&D updateJune 15, 2023 | finance.yahoo.comInvesting in Newron Pharmaceuticals (VTX:NWRN) a year ago would have delivered you a 187% gainMay 2, 2023 | markets.businessinsider.comEQS-News: Newron announces Senior Management Team changesMay 2, 2023 | uk.finance.yahoo.comNewron announces Senior Management Team changesApril 27, 2023 | finance.yahoo.comAnalysts Expect Newron Pharmaceuticals S.p.A. (VTX:NWRN) To Breakeven SoonApril 18, 2023 | uk.finance.yahoo.comNewron announces AGM 2023 resultsApril 18, 2023 | markets.businessinsider.comEQS-News: Newron announces AGM 2023 resultsMarch 28, 2023 | markets.businessinsider.comEQS-News: Newron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of PsychiatryMarch 28, 2023 | uk.finance.yahoo.comNewron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of PsychiatryMarch 17, 2023 | markets.businessinsider.comEQS-News: Newron to present at the 31st European Congress of PsychiatrySee More Headlines Receive NWPHF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Newron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:NWPHF CUSIPN/A CIKN/A Webwww.newron.com Phone(902) 610-3461Fax39-02-6103-4654Employees22Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$6.82 million Price / Sales25.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.21 per share Price / Book45.48Miscellaneous Outstanding Shares17,850,000Free FloatN/AMarket Cap$170.47 million OptionableNot Optionable Beta0.53 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Stefan Weber (Age 59)CEO & Executive Director Comp: $515.24kMr. Roberto GalliChief Financial OfficerMr. Filippo MoriggiaVice President of OperationsDr. Ravi Anand M.D. (Age 67)Ph.D., Chief Medical Officer Comp: $1.19MMs. Laura FaravelliVice President of Business DevelopmentKey CompetitorsPliant TherapeuticsNASDAQ:PLRXZymeworksNYSE:ZYMEPhibro Animal HealthNASDAQ:PAHCPraxis Precision MedicinesNASDAQ:PRAXAnaptysBioNASDAQ:ANABView All Competitors NWPHF Stock Analysis - Frequently Asked Questions How have NWPHF shares performed in 2024? Newron Pharmaceuticals' stock was trading at $5.22 at the beginning of 2024. Since then, NWPHF shares have increased by 83.0% and is now trading at $9.55. View the best growth stocks for 2024 here. Are investors shorting Newron Pharmaceuticals? Newron Pharmaceuticals saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 15,000 shares, a decline of 46.8% from the April 30th total of 28,200 shares. Based on an average daily trading volume, of 200 shares, the days-to-cover ratio is currently 75.0 days. View Newron Pharmaceuticals' Short Interest. How do I buy shares of Newron Pharmaceuticals? Shares of NWPHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:NWPHF) was last updated on 6/12/2024 by MarketBeat.com Staff From Our Partners$9 AI Model with 90% Win Rate?What if I told you it could take just $9… To win 90% of your options trades?Trade Machine | SponsoredThe Hidden Tax Advantages of America’s #1 Inheritance StockWall Street Millionaire: BUY "America's #1 Legacy Stock" The man CNBC called "The Prophet" bought AAPL at $...Stansberry Research | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Newron Pharmaceuticals S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Newron Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.